德克萨斯州 休斯顿德克萨斯大学 MD安德森癌症中心(MDACC)白血病系   教授
参与过CML、 MDS和 ALL的药物临床试验，并积极协助开发白血病的化疗和生物制剂。制定了能显著提高Ph+ALL患者生存的方案，设计了包括blinatumomab联合帕纳替尼的chemotherapy-free regimen方案，有希望进一步提高治愈率。
其目前正在研究新的治疗策略，将单克隆抗体如伊珠单抗奥唑米星（一种偶联的抗CD22抗体）和blinatumomab与最小化疗相联合。该策略将可能将成人ALL患者的治愈率提高到儿童患者的高水平。
Jabbour博士多次参加科学会议，撰写或合著了多篇出版物（> 550篇同行评审出版物）和摘要，并担任许多科学期刊的审稿人。

获得著名奖项包括：美国临床肿瘤学会(2005，2006，2007)和美国血液学会(2005，2006，2007)的成就奖。其他荣誉包括：Kimberly Patterson和Shannon Timmons研究金以及Celgene未来血液学负责人(2007)和血液学青年研究者(2016)奖。

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX
Dr. Jabbour was involved in the drug clinical trials for CML, MDS, and ALL, and has actively assisted in developing chemotherapeutic and biologic agents in leukemias. He has developed a protocol that can significantly improve the survival in Ph+ ALL patients, and investigated a chemotherapy-free regimen of the combination of blindimumab and panatinib, which is expected to further improve the cure rate.
He is currently investigating new therapeutic strategies of combining monoclonal antibodies such as inotuzumab ozogamicin, a conjugated anti-CD22 antibody, and blinatumomab with minimal chemotherapy. If successful, such strategies will likely increase the cure rates of adult patients with ALL to the high level achieved in pediatric patients.
Dr. Jabbour has participated in numerous scientific meetings, have authored or co-authored numerous publications (＞ 550 peer reviewed medical publications) and abstracts, and have served as a reviewer for several scientific journals
Awards: He received the Merit Award, American Society of Hematology and Merit Award, American Society of Hematology in 2005, 2006, and 2007.
Other honors: He also got The Kimberly Patterson Fellowship in Leukemia Research Award, The Shannon Timmins Fellowship for Leukemia Research Award, and The Celgene Future Leader in Hematology Award in 2007, and Celgene 2016 Young Investigator Award, Celgene Corporation in 2016.